Viewing nowCombinationAdikav Tablet 60/5 mg
Fimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 7.48mg
Tablet · Prescription medication · Combination
Kips Biopharma Co., Ltd.

MFDS item code 202300093 · Approved 2023.01.06 · Insurance code 693202510
Treatment of essential hypertension not controlled with fimasartan monotherapy
Used when additional treatment is needed for patients with essential hypertension whose blood pressure is not sufficiently controlled by monotherapy with pimasartan potassium.
The recommended dose of this medicine is 1 tablet once daily, taken with water, with or without food. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). It is recommended that the dose be adjusted using fimasartan before starting this medicine; however, if blood pressure is not controlled as described below, switching directly to this medicine may be considered. ㆍ 30/2.5 milligrams: Administer to patients whose blood pressure is not adequately controlled with fimasartan 30 milligrams as monotherapy. ㆍ 60/2.5 milligrams: Administer to patients whose blood pressure is not adequately controlled with fimasartan 60 milligrams as monotherapy. ㆍ 60/5 milligrams: Administer to patients whose blood pressure is not adequately controlled with fimasartan 60 milligrams as monotherapy or this medicine 60/2.5 milligrams. Patients taking fimasartan and S-amlodipine (amlodipine) concomitantly may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience. Elderly patients No initial dosage adjustment is necessary for elderly patients 70 years of age or younger. Patients with renal impairment No dosage adjustment is necessary in patients with mild to moderate renal impairment (creatinine clearance 30 ~ 80 mL/min); however, in patients with severe renal impairment (creatinine clearance < 30 mL/min), treatment should be initiated with fimasartan 30 milligrams in this medicine. Patients with hepatic impairment No dosage adjustment is necessary in patients with mild hepatic impairment; however, this medicine should not be administered to patients with moderate to severe hepatic impairment.
The safety and efficacy of this medicine in pediatric and adolescent patients 18 years of age or younger have not been established.
This medication may cause serious injury or death to the fetus and newborn if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. Individuals allergic to the active ingredient or similar compounds, those who are pregnant or breastfeeding, those undergoing kidney dialysis, those with severely impaired liver function, those with biliary obstruction, those with specific kidney diseases or diabetic nephropathy should not take this medication. Careful monitoring is necessary for individuals with low blood volume or reduced sodium levels, those with impaired kidney function, patients with renovascular hypertension, those with specific heart valve diseases, patients with severe hypotension, the elderly, and those allergic to any colorants in this medication. During the treatment, side effects such as dizziness, headache, edema, urinary disorders, insomnia, and facial flushing may occur; if symptoms are severe or persist, consult a healthcare professional. There may be instances of significant blood pressure drop, so especially when starting the medication or increasing the dose, blood pressure and condition should be closely monitored, and if hypotensive symptoms occur, one should lie down and rest and seek treatment if necessary. This medication may interact with other antihypertensive drugs, diuretics, potassium-sparing agents, etc., so if taking any other medications, it is essential to inform your healthcare provider. It is advisable to avoid this medication during pregnancy or breastfeeding, as it may have serious effects on the fetus during pregnancy; always consult a healthcare professional before taking. It is recommended not to use this medication in children under 18 years due to the lack of established safety and efficacy. For elderly patients, there is typically no need for special dosage adjustments, but caution is advised as their body may react more sensitively. Patients with severe liver impairment should not take this medication, and in cases of overdose, symptoms such as hypotension and cardiac issues may arise, necessitating immediate medical attention. This medication should be stored out of reach of children and should not be transferred to other containers for safety.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to light and should be stored in a container that blocks light. Additionally, it is best stored at room temperature, avoiding temperatures that are too cold or too hot, ideally between 1°C and 30°C.
Orange, rounded rectangular film-coated tablet
30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 7.48mg
Tablet · Prescription medication · Combination
Kips Biopharma Co., Ltd.
CombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 7.48mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
NBK Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Ajou Pharmaceuticals Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Kips Biopharma Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Bionex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.